Monoclonal Protein on Serum Protein Electrophoresis (M Component)
Monoclonal gammopathy of unknown significance (MGUS)
Low concentration of monoclonal immunoglobulins (LCMI)
Heavy chain disease
Suggested Additional Lab Testing
For multiple myeloma:
In addition to SPEP followed by immunofixation, quantitative serum immunoglobulin should be performed, because the M component must be greater than3 g/dL in the serum.
Bone marrow aspirate may be useful to show that at least 10% of the nucleated blood cells are plasma cells.
Bone marrow biopsy may be useful to show aggregates of plasma cells in focal or diffuse patterns.
CBC often reveals a normochromic normocytic anemia.
Peripheral blood smear often shows RBCs in a stacked or rouleaux formation.
For Waldenstrom macroglobulinemia:
Immunofixation to identify the M component as an IgM immunoglobulin with a quantitative IgM level greater than 3 g/dL
Serum viscosity is usually increased.
Peripheral blood smear often shows RBC aggregates in a rouleaux formation.
For heavy chain disease:
Immunofixation reveals the heavy chain as alpha, gamma, or mu.
Bone marrow examination may be informative.
Quantitative determination of the serum M component to demonstrate that an IgG or IgM monoclonal protein is less than 3.0 g/dL or an IgA monoclonal protein is less than 2.0 g/dL, or that a Bence-Jones protein is less than or equal to 1.0 g in a 24-hour urine specimen
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
- Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study
- CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma
- New Method Estimates Risk for Breast Cancer Recurrence
- Molecular Features May Predict Response in Primary Pancreatic Cancer
- Chemoimmunotherapy prolongs PFS in metastatic triple-negative breast cancer
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Open Hysterectomy Survival Rates Edge Minimally Invasive Procedures for Cervical Cancer
- The Efficacy and Safety of Apatinib for Refractory Malignancies: A Review and Meta-analysis
- Study Reveals Relationship of Sleep Duration, Diabetes Risk in Cancer Survivors
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|